Holen Sie sich die Stockscreener-App
105.67
0.43%
-0.675
Überblick
Nachrichten
Preisverlauf
Optionskette
Financials
Warum fällt GILD?
Forum
Prognose
Aktiensplit
Dividendenhistorie
Gilead Sciences Inc Aktie (GILD) Neueste Nachrichten
Gilead in $202M settlement with DoJ over kickbacks to doctors - Seeking Alpha
Gilead Sciences to pay $202 million in US settlement over HIV drug kickbacks - marketscreener.com
Gilead Sciences Agrees to Pay $202 Million Over Doctor Payments - Bloomberg.com
Gilead Sciences reaches $202 million settlement with US over kickbacks to doctors - marketscreener.com
Gilead Sciences agrees to pay $202 million to settle claims of kickbacks to doctors for HIV drug prescriptions - CNBC
Gilead Sciences (NasdaqGS:GILD) Showcases Promising Liver Disease Treatments At EASL Congress - Yahoo
Gilead presents new liver disease treatment data at EASL Congress By Investing.com - Investing.com India
Press Release Distribution & PR Platform - ACCESS Newswire
Gilead Sciences: AIDSVu Online Mapping Tool Helps Visualize HIV’s Impact in the United States - Yahoo Finance
Gilead Sciences (GILD) to Present Latest Advancements Across Primary Biliary Cholangitis and Viral Hepatitis - StreetInsider
Gilead to Present Latest Advancements Across Primary Biliary Cholangitis and Viral Hepatitis - Business Wire
Cancer Immunotherapy Market to Witness Massive Growth by 2032 | - openPR.com
Gilead Sciences Inc. stock outperforms competitors on strong trading day - MarketWatch
Nurix Therapeutics Presents Data at the AACR 2025 Annual Meeting Highlighting the Transformative Potential of Its Proprietary DEL-AI Platform Leveraging Machine Learning to Speed the Discovery of Novel Drugs - GlobeNewswire Inc.
Trump inauguration nabs $2.5M from companies, individuals in Carolinas - The Business Journals
Gilead Sciences (GILD) Adjusts EPS Outlook Despite Revenue Stabi - GuruFocus
Gilead Sciences: Dividend Investors Must Be Cautious - Seeking Alpha
Gilead Sciences, Inc. (NASDAQ:GILD) Q1 2025 Earnings Call Transcript - Insider Monkey
Gilead Sciences First Quarter 2025 Earnings: Misses Expectations - Yahoo Finance
Gilead Sciences’ Earnings Call: Growth Amid Challenges - TipRanks
Gilead Pipeline Progress Offsets Oncology Sales Slowdown - insights.citeline.com
Why Gilead Sciences Stock Slipped Today - MSN
Gilead's Kingpin Drug Missed. Is It Still A 'Safe Haven' Stock? - Investor's Business Daily
How Is The Market Feeling About Gilead Sciences? - Benzinga
Gilead Sciences' Revenue Dips, Missing Analysts' Forecasts - Finimize
Gilead leans on HIV drugs as oncology sales slow - BioPharma Dive
Gilead Delivers Lackluster Q1 Revenue on Trodelvy Miss, Oppenheimer Says - marketscreener.com
Gilead, 'closely attuned to' potential US policy shifts, stands by long-acting PrEP launch - Fierce Pharma
Gilead (GILD) Gains EMA Nod for Veklury Use in Young Children | - GuruFocus
Gilead Sciences Stock Falls as Slumping COVID-19, Cancer Drug Sales Hit Revenue - MSN
GILD Down on Q1 Earnings and Sales Miss, Oncology Sales Decline - Yahoo Finance
Gilead Sciences Q1 Earnings Review: HIV Division Masks Underperformance (GILD) - Seeking Alpha
Oppenheimer Adjusts Price Target on Gilead Sciences to $125 From $132, Maintains Outperform Rating - marketscreener.com
Gilead Sciences Earnings Were Solid. How the S&P 500’s No. 1 Health Stock Did. - Barron's
Gilead Sciences (GILD) Faces Target Price Cut Amid Revenue Short - GuruFocus
Gilead Sciences (GILD) Price Target Raised by Morgan Stanley Ami - GuruFocus
Skechers Posts Weak Revenue, Joins Intel, Gilead Sciences And Other Big Stocks Moving Lower In Friday's Pre-Market Session - Benzinga
Gilead Sciences Q1 Earnings Surpass Analyst Expectations, But Revenue Falls Short Of Estimates: Retail’s Optimistic - MSN
Gilead’s PrEP Launch Full Speed Ahead Despite Macro Pressures on HIV Space - BioSpace
Revenues flat at Gilead as HIV strength offsets oncology struggle - The Pharma Letter
Gilead Sciences (GILD) Declares Stable Dividend Amid EPS Guidance Cut - GuruFocus
Gilead Sciences Announces First Quarter 2025 Financial Results - BioSpace
Gilead Sciences Reports Strong Start to 2025 - TipRanks
Earnings call transcript: Gilead Sciences Q1 2025 Earnings Beat Expectations - Investing.com
Gilead Sciences (GILD) Posts Mixed Q1 2025 Results Amidst Produc - GuruFocus
Gilead sciences highlights potential FDA approval for lenacapavir in June 2025 - MSN
Gilead's growth plans hinge on lenacapavir after revenue miss - FirstWord Pharma
Gilead Keeping Eye On Policy But Sees Little Impact From HHS Cuts, Tariffs - insights.citeline.com
Gilead (GILD) Q1 2025 Earnings Call Transcript - AOL.com
Gilead posts profit, says HIV prevention drug on track for mid-June - Reuters
Gilead Sciences (GILD) Surpasses Earnings Estimates, Falls Short on Revenue - GuruFocus
Gilead Sciences (GILD) Lowers 2025 EPS Guidance - GuruFocus
Earnings call transcript: Gilead Sciences Q1 2025 Earnings Beat Expectations By Investing.com - Investing.com India
Gilead down 3% after hours as 2025 diluted EPS guidance lowered - Seeking Alpha
Gilead Sciences Stock Slips After Mixed Q1 Results, Lowered FY25 EPS Guidance - Benzinga
Gilead Sciences posts mixed Q1 results - Yahoo Finance
Gilead Sciences in charts: Revenue from HIV product sales grows most among segments in Q1 (GILD:NASDAQ) - Seeking Alpha
1.69%
0.52%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):